Business
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones
This new IP supports crofelemer's global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer - supporting Jaguar's strategy to secure non-dilutive ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"This new IP supports crofelemer's global exclusivity in rare pediatric intestinal failure coincident with published clinical data showing reductions in parenteral support requirements with crofelemer - supporting Jaguar's strategy to secure non-dilutive partnership funding","length":281,"tagName":"p"},{"type":"text","content":"Recent publication by members of Jaguar's Scientific Advisory Board and other intestinal failure key opinion leaders: "Targeted Literature Review and Assessment of Evidence in Microvillus Inclusion Disease (MVID)"","length":227,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / November 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that the Australian Patent Office has issued a new patent to Jaguar family company Napo Pharmaceuticals (Napo) for methods for treating short bowel syndrome (SBS), bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal, in patients with an inhibitor of chloride-ion transport such as crofelemer, Jaguar's novel plant-based prescription drug.","length":505,"tagName":"p"},{"type":"text","content":""This new patent expands the international IP protection supporting crofelemer's development in short bowel syndrome with intestinal failure (SBS-IF)," said Lisa Conte, founder, president, and CEO. "Together with emerging proof-of-concept data showing reductions in parenteral support, this strengthens the foundation for our planned business development efforts to advance crofelemer in rare pediatric intestinal failure disorders."","length":457,"tagName":"p"},{"type":"text","content":"As announced, and as presented November 8, 2025 at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting, the initial results of the ongoing and independent proof-of-concept trial of crofelemer in the UAE demonstrate disease progression modification through reduction of total parenteral support (PS) in pediatric intestinal failure patients that ranged from 12 to 37%. Specifically, in the two SBS-IF patients who have completed treatment, the results show crofelemer reduced PS between 12.5 to 15.6% at the highest dose over the 12-week treatment period, together with reduced loose watery stools frequency. For the in...